Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer

Takahito Sugase; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Kosuke Hiramatsu; Masahiro Koh; Yurina Saito; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Kazuhiro Hanazaki; Masaki Mori; Yuichiro Doki; Tetsuji Naka

doi:10.18632/oncotarget.28096

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer

PDF | How to cite

Oncotarget. 2021; 12:2232-2233. https://doi.org/10.18632/oncotarget.28096

Metrics: PDF 894 views | ?

Takahito Sugase^1,2,3, Tsuyoshi Takahashi¹, Satoshi Serada², Minoru Fujimoto², Tomoharu Ohkawara², Kosuke Hiramatsu², Masahiro Koh¹, Yurina Saito¹, Koji Tanaka¹, Yasuhiro Miyazaki¹, Tomoki Makino¹, Yukinori Kurokawa¹, Makoto Yamasaki¹, Kiyokazu Nakajima¹, Kazuhiro Hanazaki³, Masaki Mori¹, Yuichiro Doki¹ and Tetsuji Naka²

¹ Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
² Center for Intractable Immune Disease, Kochi University, Nankoku, Japan
³ Department of Surgery, Kochi University, Nankoku, Japan

Published: Ocotober 12, 2021

Copyright: © 2021 Sugase et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 1C, the image in row 2, column 2 is an accidental duplicate of the image in row 2, column 4. The corrected Figure 1C, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:32917–32928. DOI: https://doi.org/10.18632/oncotarget.25952

Figure 1: Immunohistochemical (IHC) staining for lipolysis-stimulated lipoprotein receptor (LSR) in gastric cancer (GC) patient samples. (C) Primary GC, lymph node metastasis, and distant metastasis (peritoneum and liver) of 7 patients with GC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28096

Publication Alerts

Corrections:

Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer